Skip to main content

Retatrutide Integration Plan for gray.guide (UPDATED)

Executive Summary​

Retatrutide is NOW AVAILABLE in the gray market as a triple agonist (GLP-1/GIP/glucagon) medication. With verified 99%+ purity from Janoshik testing and availability through existing vendor Alex Wu, immediate integration is required to serve users seeking this advanced weight loss option.

Current Gray Market Status​

Availability​

  • Status: Currently available through gray market vendors
  • Verified Vendor: Alex Wu
  • Available Doses: 5mg, 10mg, 12mg, 15mg, 20mg, 30mg
  • Form: Lyophilized powder (Path C)
  • Testing: All doses tested at 99%+ purity by Janoshik Labs (no impurities or toxins detected)

Key Differences from Clinical Trials​

  • Gray market doses extend up to 30mg (vs. 12mg max in trials)
  • Only available as powder requiring reconstitution
  • No manufacturer pens or vials yet available

Immediate Implementation Plan​

Phase 1: Critical Updates (Complete within 48 hours)​

1.1 Update Vendor Information​

File: /src/data/vendors.json

  • Add Retatrutide to Alex Wu's product offerings
  • Include all available doses (5, 10, 12, 15, 20, 30mg)
  • Add Janoshik testing verification badge

1.2 Update Book Introduction​

File: /docs/book-introduction.md

Title: "Sourcing Mounjaro/Zepbound/Tirzepatide, Ozempic/Wegovy/Semaglutide & Retatrutide | The Overseas Sourcing Guide"

Add paragraph after current intro:
"NEW: Retatrutide, the revolutionary triple agonist targeting GLP-1, GIP, and glucagon receptors, is now available through select gray market vendors. Offering potentially superior weight loss compared to dual and single agonists, Retatrutide represents the cutting edge of GLP-1 therapy."

1.3 Create Retatrutide Dosing Tab​

File: /docs/universal-safety/dosing-principles.mdx Add new tab with:

  • Starting dose: 1-2mg weekly (extrapolated from trials)
  • Titration: Increase by 1-2mg every 4 weeks
  • Therapeutic range: 5-15mg (based on clinical data)
  • Maximum gray market dose: 30mg (use with extreme caution)
  • Strong warning about exceeding clinical trial doses

Phase 2: Comprehensive Documentation (Complete within 1 week)​

2.1 Create Medication Comparison Page​

New File: /docs/getting-started/medication-comparison.mdx

---
title: "Comparing GLP-1 Medications: Semaglutide vs Tirzepatide vs Retatrutide"
sidebar_position: 2
---

# GLP-1 Medication Comparison Guide

## Quick Comparison Table
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---------|-------------|-------------|-------------|
| Mechanism | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Avg Weight Loss | ~15% at 68 weeks | ~21% at 72 weeks | ~24% at 48 weeks |
| Gray Market Availability | Wide | Wide | Limited (Alex Wu verified) |
| Forms Available | Pens, Vials, Powder | Pens, Vials, Powder | Powder only |
| Typical Dose Range | 0.25-2.4mg | 2.5-15mg | 5-15mg (up to 30mg available) |

[Include detailed comparison sections with tabs]

2.2 Update Path C Documentation​

File: /docs/path-guides/path-c-diy-powder/README.md

  • Add Retatrutide to the list of available peptides
  • Include specific reconstitution considerations
  • Reference Janoshik testing results

2.3 Create Retatrutide-Specific Dosage Calculation Examples​

File: /docs/path-guides/path-c-diy-powder/dosage-calculation.md Add section:

### Retatrutide Calculation Examples
Given the higher mg amounts in Retatrutide vials:
- 10mg vial + 1mL BAC water = 10mg/mL concentration
- For 5mg dose: draw 0.5mL (50 units on U-100 syringe)
- For 7.5mg dose: draw 0.75mL (75 units on U-100 syringe)

Phase 3: Safety & Education Focus (Complete within 2 weeks)​

3.1 Enhanced Safety Warnings​

File: /docs/universal-safety/risks-side-effects.md Add Retatrutide section:

  • Triple agonist mechanism means potentially different side effect profile
  • Heart rate increases noted in trials
  • Limited long-term safety data
  • Extra caution with doses exceeding 15mg (beyond clinical trial range)

3.2 Create Retatrutide Decision Guide​

New File: /docs/getting-started/choosing-retatrutide.md

  • Who should consider Retatrutide
  • Comparison with other GLP-1s
  • Risk-benefit analysis
  • Importance of starting low despite high mg vials

Phase 4: Technical Updates (Complete within 2 weeks)​

4.1 Update Components​

  • Modify DosingSteps component to include Retatrutide
  • Update SupplyComparison component for three medications
  • Add Retatrutide filter to vendor listing

4.2 Create Alerts/Badges​

  • "New" badge for Retatrutide content
  • "Limited Availability" warning
  • "Janoshik Verified" badge for Alex Wu

Content Guidelines​

Messaging Strategy​

  1. Position as Advanced Option: For experienced GLP-1 users or those seeking maximum efficacy
  2. Emphasize Testing: Highlight Janoshik verification
  3. Safety First: Strong warnings about exceeding clinical doses
  4. Limited Availability: Set expectations about vendor options

Key Safety Messages​

  • Start with lowest available dose (5mg) despite vial size
  • Gray market doses exceed clinical trial maximums
  • Triple agonist = potentially different effects
  • Mandatory medical supervision recommendation

Implementation Checklist​

Week 1 Tasks​

  • Update Alex Wu vendor listing with Retatrutide
  • Modify book introduction title and content
  • Add Retatrutide tab to dosing principles
  • Create basic medication comparison page
  • Update Path C powder guide

Week 2 Tasks​

  • Complete detailed comparison content
  • Add Retatrutide dosage calculations
  • Create safety warnings specific to Retatrutide
  • Update all relevant components
  • Deploy vendor filtering for Retatrutide

Ongoing Tasks​

  • Monitor user feedback and questions
  • Track additional vendor availability
  • Update with new clinical data as published
  • Collect gray market user experiences
  • Consider creating Retatrutide-specific FAQ

Success Metrics​

  • Clear communication of Retatrutide availability
  • Users understand it's an advanced option
  • Safety warnings prominently displayed
  • Easy vendor identification (Alex Wu)
  • Proper dosing guidance despite high mg vials

Notes for AI Agents​

  • Retatrutide content should emphasize it's the newest, most advanced option
  • Always include safety warnings about exceeding clinical trial doses
  • Reference Janoshik testing when mentioning Alex Wu
  • Use Path C (DIY powder) framework for all Retatrutide content
  • Consider creating comparison graphics showing single vs dual vs triple agonist
By Mr Fox
Published April 17, 2025